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Artesunate is the most effective treatment for severe ma-
laria. However, delayed-onset hemolytic anemia has been 
observed in ≈20% of travelers who receive artesunate, 
≈60% of whom require transfusion. This finding could dis-
courage physicians from using artesunate. We prospec-
tively evaluated a cohort of 123 patients in France who had 
severe imported malaria that was treated with artesunate; 
our evaluation focused on outcome, adverse events, and 
postartesunate delayed-onset hemolysis (PADH). Of the 
123 patients, 6 (5%) died. Overall, 97 adverse events oc-
curred. Among the 78 patients who received follow-up for 
>8 days after treatment initiation, 76 (97%) had anemia, 
and 21 (27%) of the 78 cases were recorded as PADH. The 
median drop in hemoglobin levels was 1.3 g/dL; 15% of pa-
tients with PADH had hemoglobin levels of <7 g/dL, and 1 
required transfusion. Despite the high incidence of PADH, 
the resulting anemia remained mild in 85% of cases. This 
reassuring result confirms the safety and therapeutic benefit 
of artesunate.
Intravenous (IV) artesunate has been the recommended first-line treatment for severe malaria worldwide since 
2010 (1). Two large randomized trials showed a 35.0% 
reduction (from 22.0% to 15.0%) in death rates among 
adults in Asia and a 22.5% (from 10.9% to 8.5%) reduction 
among children in Africa when artesunate was compared 
with parenteral quinine in the treatment of severe malaria 
(2,3). Four case series performed in Western countries re-
ported death rates of <4% (4–7).
Artesunate is generally considered safe (8). Howev-
er, its use in Western countries has shown that delayed 
hemolytic events occur in ≈20% of patients with severe 
imported malaria, and 60% of these patients require blood 
transfusion (4,6,7,9–11). Delayed-onset anemia (herein 
referred to as postartesunate delayed-onset hemolysis 
[PADH] pattern of anemia) has been observed to occur 
2–3 weeks after initiation of IV artesunate, after complete 
clearance of parasites, and to resolve during weeks 3–6 
(7). The mechanism of this anemia is hemolytic, as dem-
onstrated by high serum lactate dehydrogenase (LDH) and 
low plasma haptoglobin levels. Across several studies, no 
common conventional cause of hemolysis was identified 
(4,6,12–14). In a comparative study, PADH anemia was 
described in 5 of 8 patients with hyperparasitemia treated 
with artesunate alone or combined with quinine; it was 
not seen in patients treated with quinine alone. This find-
ing supports the assumption that this side effect is associ-
ated with artesunate (11). PADH anemia has not been re-
ported in meta-analyses (8) nor observed in large clinical 
trials (2,3). However PADH has been reported recently in 
children in Africa (15).
This PADH is a matter of concern for the medical com-
munity. Without a systematic assessment of the incidence 
and outcome of artesunate-associated PADH anemia, a 
slowdown may occur in the ongoing change toward favor-
ing treatment with artesunate rather than quinine, a less-
efficient treatment for severe malaria. The World Health 
Organization recently recommended increased vigilance 
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for PADH anemia and called for a more precise description 
of its incidence, time course, and severity (16). To deter-
mine the effectiveness and safety of artesunate in patients 
with severe imported malaria, we focused on PADH ane-
mia cases detected through an existing artesunate surveil-
lance program in France.
Materials and Methods
Temporary Use Authorization Program and Treatment
In May 2011, IV artesunate (60-mg vial of powder and sol-
vent) became available in France through the Agence Natio-
nale de Sécurité du Médicament, the French national drug 
agency. The product, manufactured by Guilin Laboratories 
in China, was imported to Europe by ACE Pharmaceuti-
cals. Within the framework of a temporary use authoriza-
tion program, data were prospectively collected during May 
2011–May 2013 from medical charts and by using Agence 
Nationale de Sécurité du Médicament forms that were com-
pleted by attending physicians at the beginning and end of 
treatment. A dedicated team at the National Reference Cen-
ter for Malaria (NRCM) retrieved the data. Additional data 
were obtained from the national pharmacovigilance system 
and an NRCM database, as described (17). Retrieved data 
included age, sex, native country, place of malaria acquisi-
tion, immunocompromised status, pregnancy status, appro-
priateness of chemoprophylaxis, purpose of travel, duration 
of disease before treatment, location where artesunate was 
prescribed, drug used as first-line treatment, median dura-
tion/dose of artesunate treatment, duration of hospitaliza-
tion, outcome, clinical and biologic criteria for severe ma-
laria, and duration of follow-up. The artesunate database 
was implemented and informed consent was obtained from 
patients in accordance with a procedure common to all 
French National Reference Centers (http://www.legifrance.
gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000810
056&dateTexte=&categorieLien=id). Data were collected 
and analyzed anonymously. After diagnosis, all patients 
received IV artesunate (2.4 mg/kg) at 0, 12, and 24 hours 
and daily thereafter until oral antimalarial treatment could 
be administered to complete treatment as recommended in 
France (18). For patients who received a full 7-day course 
of IV artesunate, no other treatment was administered.
Case Definitions
Severe malaria was defined as malaria in persons with 
blood smears positive for asexual forms of Plasmodium 
falciparum parasites and at least 1 criterion of severity ac-
cording to the definition of severe malaria used in France 
(19,20). Patients with mixed-species infections were ex-
cluded from analysis.
Anemia was defined as a blood hemoglobin level of 
<12 g/dL in female and <13 g/dL in male patients (reference 
values 12.0–16.5 and 13.0–17.5 g/dL, respectively). Hemo-
lysis was defined as a plasma haptoglobin level of <0.1 g/L 
(reference value 0.55–2.50 g/L), plasma lactic dehydroge-
nase (LDH) level of >390 IU/L (reference value 190–390 
IU/L), or both. We defined 3 patterns of anemia as previ-
ously described (7,10,11): PADH, non-PADH, and indeter-
minate. The PADH pattern was defined by 1) a new drop 
in the hemoglobin level after day 8 of treatment initiation 
and the appearance or reappearance of hemolytic markers 
(>10% drop in hemoglobin or >10% rise in LDH levels) 
occurring any time between day 8 and the end of follow-up 
and/or 2) by any information in the medical chart referring 
to acute hemolysis occurring after day 8. The non-PADH 
pattern was defined by a hemoglobin nadir and a hemolysis 
peak occurring before day 8, with or without positive mark-
ers of hemolysis after day 8 and without a nadir or sudden 
drop of hemoglobin after day 8 as defined for the PADH 
pattern. The indeterminate pattern was defined as all other 
cases of anemia for which information was lacking or with 
an evolution pattern that did not fit the other patterns.
Sample Collection
Blood samples were routinely collected from the patients 
on days 0, 2 (±1), 7 (±2), 14 (±3), 21 (±3), and 28 (±3) 
after treatment initiation (18,21). Samples were analyzed 
to determine the levels of hemoglobin, total bilirubin, glu-
cose, plasma bicarbonate, lactate, serum creatinine, blood 
urea nitrogen, LDH, haptoglobin, and parasitemia and the 
reticulocyte count. 
Cure, Evolution, and Side Effects
The death rate at day 28 was the main clinical endpoint. 
Parasitological cure was defined as a P. falciparum–nega-
tive blood smear on day 7, with possible confirmation lat-
er. Relapse was defined as the reappearance of fever and 
a blood smear positive for asexual P. falciparum parasite 
forms at any time after a first negative result during the 
28-day follow-up period. All side effects reported on medi-
cal charts were recorded and graded by using the National 




Travel characteristics and demographic, clinical, and lab-
oratory variables were evaluated. Quantitative variables 
were expressed as medians (quartiles 1–3 [Q1–3]) or, when 
appropriate, as means (SEMs). Qualitative variables were 
expressed as percentages. Differences between groups 
(survivors vs. nonsurvivors, patterns of anemia) were ana-
lyzed by using the Fisher exact test for categorical variables 
and Mann-Whitney test for continuous variables. Statisti-
cal analyses were performed by using IBM SPSS Statistics 
Delayed-Onset Hemolytic Anemia and Artesunate
version 20 (IBM, Armonk, NY, USA). All reported p 
values are 2-tailed.
Results
General Presentation of Cohort
A study flowchart is provided in Figure 1. Demographic 
and clinical characteristics of the 123 patients who re-
ceived artesunate treatment are summarized in online 
Technical Appendix Table 1 (http://wwwnc.cdc.gov/EID/
article/21/5/14-1171-Techapp1.pdf).
Effectiveness
Among the 123 patients with severe malaria treated with 
artesunate, 117 fully or partially recovered and 6 died from 
malaria (death rate 4.9%, 95% CI 2.0–10.8). All deaths 
were related to severe multiorgan failure and occurred 
within 3 days of receiving artesunate. 
The following characteristics were seen more fre-
quently at admission in patients who died versus those who 
survived: lower median Glasgow Coma Scale (median 
score 10 [Q1–3: 3–13]) vs. 14 [Q1–3: 14–15], p = 0.001; 
reference score 15); respiratory distress (50% [3/6] vs. 9% 
[11/117], p = 0.019); higher median parasitemia level (11% 
[Q1–3: 8–26] vs. 6% [Q1–3: 2–10], p = 0.05); higher me-
dian lactate level (10 mmol/L [Q1–3: 3–12] vs. 2 mmol/L 
[Q1–3: 2–3], p = 0.002; reference value <1.8 mmol/L); 
higher total bilirubin concentration (98 µmol/L [Q1–3: 98–
209] vs. 49 µmol/L [Q1–3: 26–75], p = 0.007; reference 
value 2–17 mmol/L); lower glucose level (<2.2 mmol/L in 
50% [3/6] vs. <2.2 mmol/L in 3% [4/117], p = 0.002; refer-
ence value 3.9–5.8 mmol/L); and renal insufficiency (80% 
[5/6] vs. 9% [11/117], p<0.001). Age, sex, immunocom-
promised state, place of malaria acquisition, cardiocircula-
tory impairment (p = 0.098), and severe anemia at day 0 
were not significantly associated with death. The median 
time between symptom onset and initiation of artesunate 
treatment was 1.5 days (Q1–3: 1–5) in the 6 patients who 
died versus 4.0 days (Q1–3: 2–5) in those who survived 
(p = 0.13). Artesunate was used as second-line treatment 
after quinine in 2 of 6 patients who died versus 49 of 117 
patients who survived (p = 1). All survivors had complete 
parasite clearance before treatment day 7. Only 1 relapse 
was observed; it occurred 26 days after a 3-day course of 
IV artesunate that was not followed by the recommended 
oral course of antimalarial drug therapy.
Safety
Safety data were available for days 0–8 and 9–28 for 123 
and 78 patients, respectively. All reported adverse events 
resolved during follow-up. A summary of the severity of 
reported adverse events possibly associated with artesunate 
is shown in Table 1. 
Rash, telogen effluvium, and mild pruritus were re-
corded for 1 patient each. The rash occurred several days af-
ter the end of artesunate administration and was considered 
unrelated to artesunate. Telogen effluvium was diagnosed 
Figure 1. Distribution of PADH and non-PADH patterns of anemia 
in a prospective analysis of delayed-onset hemolytic anemia in 
patients with severe imported malaria treated with artesunate, 
France, 2011–2013. Of 123 patients who received treatment, 6 
died and 39 were lost to follow-up after day 8, leaving a total of 78 
patients with sufficient clinical and/or biologic information to fulfill 
the anemia definition criteria for PADH or non-PADH classification. 
Indeterminate pattern, cases of anemia for which information was 
lacking or with an evolution pattern that did not fit PADH or non-
PADH patterns; PADH, postartesunate delayed-onset hemolysis.
RESEARCH
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during the 28 days following treatment initiation. The pru-
ritus occurred during artesunate treatment and disappeared 
without intervention. 
Liver enzyme levels increased in 8/117 patients 
who survived, including 6 who concurrently received >1 
medication(s) with liver toxicity as a potential side effect 
(paracetamol [acetaminophen] or nonsteroidal antiinflam-
matory drug). All these episodes occurred before day 8. 
Vision loss occurred in 1 patient and was considered by 
the attending ophthalmologist to be associated with hy-
pertensive retinopathy. Two cases of acute cerebellar 
syndrome occurred; both were thought to be associated 
with a postmalaria neurologic syndrome. Tinnitus was re-
ported in 1 patient who received quinine just before arte-
sunate. One patient experienced continuous tremors that 
resolved spontaneously. 
QTc lengthening (i.e., corrected lengthening of the in-
terval between start of the Q wave and end of the T wave in 
the heart’s electrical cycle) and transient bradycardia were 
recorded for 1 and 2 patients, respectively. One transient 
bradycardia (54 bpm) episode occurred between 2 artesu-
nate injections and resolved spontaneously. In the patient 
with QTc lengthening (460 ms; reference value <440 ms), 
artesunate treatment (total dose 480 mg) was changed to 
artemether/lumefantrine (4 tablets, each with 20 mg arte-
mether and 120 mg lumefantrine) and then to atovaquone/
proguanil (4 tablets/d for 3 d, each with 250 mg atovaquone 
and 100 mg proguanil) because of persistent QTc length-
ening (560 ms) accompanied by low potassium levels (<3 
mmol/L; reference range 3.5–5.0 mmol/L). These 2 pa-
tients were 13 and 15 years of age and weighed 62 kg and 
40 kg, respectively. Another patient experienced severe 
disseminated intravascular coagulation that led to arterial 
ischemia of extremities and central nervous system isch-
emia (caudate nuclei, corona radiate, and white matter). 
Amputation of fingers and legs was necessary. All sequelae 
in this patient were considered related to severe malaria. 
One patient with myasthenia gravis received artesu-
nate and experienced no worsening of the disease (22). 
Four patients were pregnant; 1 of the pregnancies was dis-
covered during therapy. One miscarriage occurred; hemor-
rhage led to a blood transfusion. Artesunate was well toler-
ated in 2 women during the second and third trimesters and 
in 1 during labor. Hypoglycemia was not recorded during 
artesunate treatment.
Anemia, Hemolysis, and Transfusion
Anemia commonly occurred, was slow to resolve, and 
followed variable patterns (Figures 1, 2). Of the 78 pa-
tients with appropriate follow-up, 76 (97.4%, 95% CI 
91.0%–99.7%) experienced anemia (Figure 1). The non-
PADH and PADH patterns were observed in 51 (65.4%, 
95% CI 53.8%–75.8%) and 21 (26.9%, 95% CI 17.5%–
38.2%) patients, respectively, with or without transfusion, 
who received clinical and/or laboratory follow-up beyond 
day 8. In the PADH group, hemoglobin levels dropped 
a median of 1.3 g/dL from day 7 (±2) to day 14 (±3), 
but levels ranged from 4.6 g/dL to 12.9 g/dL on day 14 
(±3). During days 11–27, a total of 8 patients had severe 
anemia, of whom 4 experienced typical PADH anemia (p 
= 0.4) (Figure 2). Of the 21 total patients with PADH, 
3 (14.3%, 95% CI 3.1%–36.3%) had blood hemoglobin 
levels of <7 g/dL (6.2, 4.6, and 6.3 g/dL) during week 2 
after treatment initiation.
With the exception of hemoglobin level, no parameters 
were significantly associated with a particular anemia pat-
tern (Table 2; online Technical Appendix Table 2); median 
hemoglobin levels at day 0 were estimated to be 11.3 g/dL 
(Q1–Q3: 9.6–13.1) and 13.6 g/dL (Q1–Q3: 11.6–15.4), re-
spectively, for patients with non-PADH and PADH anemia 
 
Table 1. Severity of reported adverse events possibly associated with artesunate treatment of severe imported malaria in 117 patients, 
France, 2011–2013* 
Adverse event 






Grade 4, life 
threatening  Total 
Cutaneous 2† 1‡ 0 0 3 
Ataxia, tremor, CNS ischemia 0 2 1 1 4 
Tinnitus 1 0 0 0 1 
Cardiac and arterial ischemia 1 1 1 1 4 
Hypertension 0 0 1§ 0 1 
Elevated level of ALT 2 2 3 1 8 
Hyperkalemia 1 0 0 0 1 
Anemia¶ 20 11 27 17 75 
Total 27 17 33 20 97 
*Adverse events were obtained from medical charts and graded by using the National Institutes of Health classification for side effects 
(http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf). ALT, alanine transaminase; CNS, central 
nervous system. 
†Mild pruritus and rash. 
‡Telogen effluvium. 
§Regressive retinopathy. 
¶Grading was done during the follow-up by using available nadir of hemoglobin. For HIV-negative patients, the severity of anemia was graded as follows: 
grade 1, 10.0–10.9 g/dL; grade 2, 9.0–9.9 g/dL; grade 3, 7.0–8.9 g/dL, grade 4, <7.0 g/dL. For HIV-positive patients, the severity of anemia was graded as 
follows: grade 1, 8.5–10.0 g/dL; grade 2.0, 7.5–8.4 g/dL; grade 3, 6.5–7.4 g/dL; grade 4, <6.5 g/dL. 
 
(p = 0.002) (Tables 2, 3). The incidence of the PADH ane-
mia did not differ between patients who received artesu-
nate as first-line treatment and those who received quinine 
before being switched to artesunate (p = 0.38, Fisher ex-
act test). During week 2, the rise in LDH levels and the 
drop in haptoglobin levels were consistent with hemolytic 
anemia in the PADH group (Figure 3); these changes lasted 
≈1–2 weeks. Median LDH levels remained high at days 21 
(724 IU/L [range 344–1,564] and 28 (497 IU/L [range 177–
922]). Haptoglobin remained undetectable during weeks 2 
and 3 (Table 3; Figure 3). During subsequent weeks, hemo-
globin levels rose slowly in the non-PADH group (Table 3). 
Maximum reticulocyte production occurred during weeks 
2 and 3 for the non-PADH and PADH groups, respectively 
(Figure 3; Table 3). At day 28, patients in both groups had 
hemoglobin levels >11 g/dL.
Of the 78 patients, 15 (19.3%, 95% CI 10.5%–28.0%) 
received a total of 20 blood transfusions, 15 (75%) of which 
were performed before day 8, during the acute phase of the 
disease (Figure 1). Among the 21 patients with delayed he-
molysis, 1 (4.8%, 95% CI 0.1%–23.8%) had a blood trans-
fusion after day 8 (hemoglobin nadir 6.3 g/dL). No deaths 
were related to any side effects, including anemia.
Discussion
According to NRCM data, each year in France, ≈250 pa-
tients are treated for severe imported malaria. In this cohort 
of 123 patients treated for severe malaria in high-care set-
tings, IV artesunate was effective and generally safe. The 
death rate was 5%, and blood transfusion was necessary for 
<20% of all patients and for <5% of patients with PADH 
anemia. Compared with retrospective case series, our pro-
spective approach reduced bias toward severe anemia cases 
and provided a robust evaluation of artesunate safety, par-
ticularly as concerns PADH anemia.
Figure 2. Nadir and last hemoglobin levels for 78 patients in 
a prospective analysis of delayed-onset hemolytic anemia in 
patients with severe imported malaria treated with artesunate, 
France, 2011–2013. Gray dots, hemoglobin level for patients with 
the postartesunate delayed-onset hemolysis (PADH) pattern of 
anemia; black dots, hemoglobin level for patients with non-PADH 
pattern of anemia, indeterminate pattern and nonanemic patients. 
Dotted lines represent hemoglobin level thresholds of 8 or 7 g/dL. 
 
Table 2. Association between selected variables and non-PADH and PADH patterns of anemia in 72 patients with severe imported 
malaria treated with artesunate, France, 2011–2013* 
Variable 
Pattern 
p value Non-PADH, n = 51† PADH, n = 21‡ 
Sex, no. (%) 
 M 29 (57) 11 (52) 0.8§ 
 F 22 (43) 10 (48)  
Age, y, median (Q1–Q3) 42 (27–52) 41 (31–53) 0.7¶ 
Location of birth, no. (%)    
 Africa 31 (61) 10 (48) 0.3§ 
 Europe, North America 18 (35) 11 (52)  
 South, Central America 2 (4) 0  
 Asia 0 0  
Duration of illness before artesunate treatment, median d (Q1–Q3) 4 (3–5) 4 (3–5) 0.8¶ 
Hyperparasitemia, no. (%)    
 >4% infected erythrocytes 28 (55) 16 (76) 0.1§ 
 >10% infected erythrocytes 13 (25) 5 (24) 1§ 
Parasitemia level at day 0, median % infected erythrocytes (Q1–Q3) 5.0 (1.4–10.1) 7.1 (3.75–14.5) 0.1¶ 
Hemoglobin level, median g/dL (Q1–Q3), at day 0 11.3 (9.6–13.1) 13.6 (11.6–15.4) 0.002¶ 
Total dose of artesunate, median mg (Q1–Q3) 840 (540–1035) 800 (676–955) 0.8¶ 
Artesunate first-line treatment for current severe malaria episode, no. (%) 29 (57) 15 (71) 0.3§ 
*PADH, postartesunate delayed-onset hemolysis; Q1–Q3, quartiles 1–3. 
†Non-PADH pattern was defined by a hemoglobin nadir and a hemolysis peak occurring before day 8, with or without positive markers of hemolysis after 
day 8 and without a nadir or sudden drop of hemoglobin after day 8. 
‡PADH pattern was defined by 1) a new drop in the hemoglobin level after day 8 of treatment initiation and the appearance or reappearance of hemolytic 
markers occurring any time between day 8 and the end of follow-up and/or 2) by any information in the medical chart referring to acute hemolysis 
occurring after day 8. 
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The 5% death rate in this cohort is lower than rates 
observed among artesunate-treated adults who received 
treatment in malaria-endemic countries (2,3) but similar to 
rates among smaller cohorts of travelers from non–malaria-
endemic countries whose treatment was managed in facili-
ties with high levels of care (23,24). A retrospective study 
in the United Kingdom that compared 143 quinine-treated 
patients with 24 artesunate-treated patients reported no 
deaths, fewer intensive care unit admissions, and shorter 
durations of hospitalization for artesunate-treated patients 
(25). In a study of 400 severe imported P. falciparum ma-
laria cases treated with quinine (10% death rate), the ma-
jor factors associated with death were low Glasgow Coma 
Scale score, respiratory failure, severe renal impairment, 
hyperlactemia, or hypoglycemia (23) during the first 24 
hours after admission. Despite our use of different data-
capture methods and severity scores, we found the same 
factors associated with death in this cohort of artesunate-
treated patients.
PADH occurred in 27% of patients in this study, but 
it was rarely associated with severe anemia and was never 
fatal. Previous observations (7) may have been partially 
biased toward the most severe cases; in contrast, our pro-
spective approach efficiently captured asymptomatic mild 
or moderate anemia cases. In our study, the median delayed 
drop in hemoglobin levels was 1.3 g/dL. Although PADH 
accounted for most of the severe anemia cases (Figure 2), 
only 3 (15%) patients had hemoglobin levels of <7 g/dL, 
and only 1 received a transfusion. This transfusion rate 
(<5%) is markedly lower than that previously reported for 
patients with severe imported malaria and delayed-onset 
anemia (≈60%) (4,6,7,11,13). Taken together, our results 
demonstrate that, in the setting of severe imported malaria, 
delayed hemolysis does not alter the life-saving effect of 
IV artesunate, but it does need focused medical attention 
and follow-up.
With the exception of the pretreatment hemoglobin 
level, no parameters, including the cumulative dose of arte-
sunate and initial parasitemia levels, were correlated with 
the risk for delayed hemolysis in our study. Some authors 
have associated high parasitemia levels with delayed-onset 
hemolysis (6,7,11); others have demonstrated that not all 
patients with high parasitemia levels experience late-onset 
hemolysis (4). Other factors are related to the peculiar 
mode of action linked to artemisinin derivatives and are 
probably involved in delayed-onset hemolysis (4,26). In-
dications pointing to the involvement of pitting (27,28), a 
process whereby dead parasites are expelled from infected 
erythrocytes, has been reported (29,30). We have shown 
that the risk for PADH is linked to the peak number of 
pitted erythrocytes rather than the absolute initial level of 
parasitemia (31).
Side effects of artesunate frequently include gastroin-
testinal disturbances, neutropenia (1.3%), reticulocytope-
nia (0.6%), and elevated liver enzymes (1.1%) (32–34). In 
studies of patients with travel-associated malaria treated in 
non–malaria-endemic countries, no severe hemodynamic, 
cardiac, or allergic reactions were attributed to artesunate 
(4,5,7,11). Artesunate is considered potentially cardiotoxic 
at doses >15 mg/kg (32). However, in our study, mild to 
moderate cardiotoxicity developed in 3 patients treated 
with the recommended 2.4-mg/kg dose. The patients were 
 
Table 3. Laboratory values for 72 patients with artesunate-treated severe imported malaria and a PADH or non-PADH pattern of 
anemia during days 0–28 after treatment initiation, France, 2011–2013* 
Patient group, laboratory test 
Median value (range), no. results available  
Day 0 Day 7 Day 14 Day 21 Day 28 
Non-PADH†      
 Hemoglobin level, g/dL‡ 11.3 (5.9–16.6), 
51 
9.2 (5.7–13.1),  
62 






 Reticulocyte count, G/L 61 (3–183), 16 60 (2–444), 25 156 (75–412), 20 108 (56–204), 12 73 (34–100), 12 






521 (201–905),  
12 
464 (240–798),  
15 
 Haptoglobin level, g/L 0.05 (0.00–2.20), 
8 
0 (0.00–2.90),  
25 
0 (0.00–2.50),  
20 




PADH§      








11.1 (10–15),  
17 
 Reticulocyte count, G/L 61 (61–61), 1 34 (8–132), 12 124 (63–315), 15 162 (90–431), 12 127 (63–223), 13 
 LDH level, IU/L 846 (293–1,195), 
9 






497 (177–922),  
14 
 Haptoglobin level, g/L 0 (0.00–0.20), 5 0 (0.00–1.50), 15 0 (0.00–0.60), 18 0 (0.00–0.00), 13 0 (0.00–1.50), 15 
*G/L, Giga/L; LDH, lactate dehydrogenase; PADH, postartesunate delayed-onset hemolysis.  
†Non-PADH pattern was defined by a hemoglobin nadir and a hemolysis peak occurring before day 8, with or without positive markers of hemolysis after 
day 8 and without a nadir or sudden drop of hemoglobin after day 8.  
‡Median drop in hemoglobin during the first week of treatment was 2.1 g/dL. 
§PADH pattern was defined by 1) a new drop in the hemoglobin level after day 8 of treatment initiation and the appearance or reappearance of hemolytic 
markers (defined as >10% drop in hemoglobin or >10% rise in LDH levels) occurring any time between day 8 and the end of follow-up and/or 2) by any 
information in the medical chart referring to acute hemolysis occurring after day 8. 
¶Median drop in hemoglobin during the first week of treatment was 2.4 g/dL. 
 
rapidly switched to another therapy, and the signs and 
symptoms of cardiotoxicity disappeared. Whether these 
cardiac episodes were related to artesunate is not clear. In a 
study performed in Bangladesh involving 21 adults with se-
vere malaria treated with artesunate, 2 patients experienced 
QTc lengthening (>500 ms), but, as observed in 1 of our 
patients, hypokalemia was present (35). None of the other 
side effects reported as possibly attributable to artesunate 
in other studies (e.g., dizziness, nausea, diarrhea, anorexia, 
metallic taste in the mouth) were recorded in this cohort, 
and the neurologic episodes were considered to be related 
to malaria rather than artesunate by the attending physi-
cians. As reported for artesunate-associated side effects in 
other studies, those in our study were generally mild.
This study has limitations. The prospective surveil-
lance system implemented in France relies on the motiva-
tion of attending physicians and parasitologists to report 
data to the NRCM team because the reporting of imported 
malaria cases is not compulsory in metropolitan France. 
Thus, some adverse events might have been overlooked. 
In addition, patients with PADH whose anemia was well 
tolerated may have gone unreported or been lost to follow-
up. Furthermore, symptoms of slight delayed anemia may 
be confused with slow clinical recovery from severe ma-
laria and thus remain undetected. In addition, it is likely 
that the 39 patients who were lost to follow-up recovered 
without problems instead of remaining as postinfectious 
patients with continuing problems. A rapid analysis, ex-
cluding patients who died, did not show any differences in 
demographic variables or length of hospital/intensive care 
unit stay between the group that was followed for 28 days 
and the group that was followed <8 days (data not shown). 
Nevertheless, it is unlikely that severe cases of delayed he-
molysis or other severe side effects would be overlooked 
in a temporary use authorization program implemented at 
facilities with high levels of care, and, as mentioned, this 
study captured a fairly high proportion of mild to moderate 
cases of delayed hemolysis. Furthermore, the study was not 
randomized, but in the setting of severe imported malaria, 
it is considered unethical to repeat artesunate versus qui-
nine trials already performed in malaria-endemic countries 
(3,36). The decision to use artesunate or quinine was left to 
the attending physician, but use of artesunate was mostly 
related to its availability at the hospital. It is unlikely that 
the decision to use/not use artesunate as a first-line treat-
ment was made according to the clinical severity of disease 
in a patient.
Our prospective analysis joins other reports (16,37) 
in confirming the very favorable risk-to-benefit ratio of IV 
artesunate in the treatment of severe imported malaria, de-
spite PADH anemia. Our results show that, in this setting, 
delayed hemolysis did not alter the life-saving effect of IV 
artesunate. Delayed hemolysis was a common occurrence 
among the patients but resulted in very low levels of he-
moglobin in ≈15% of cases. To ensure the appropriate di-
agnosis and treatment of severe anemia, the World Health 
Organization and national entities recommend that hemo-
globin levels be assessed weekly for 1 month after artesu-
nate administration (16,18,21). Further studies are needed 
to find predictive markers of hemolysis and anemia to fa-
cilitate posttreatment follow-up in travelers to and children 
in malaria-endemic countries (10–12,31).
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